Your browser is no longer supported. Please, upgrade your browser.
Settings
GNMX Aevi Genomic Medicine, Inc. daily Stock Chart
GNMX [NASD]
Aevi Genomic Medicine, Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own15.00% Shs Outstand38.02M Perf Week37.30%
Market Cap65.77M Forward P/E- EPS next Y-0.75 Insider Trans17.22% Shs Float27.02M Perf Month36.22%
Income-38.00M PEG- EPS next Q-0.22 Inst Own21.20% Short Float2.18% Perf Quarter33.08%
Sales- P/S- EPS this Y16.00% Inst Trans- Short Ratio1.83 Perf Half Y21.83%
Book/sh0.48 P/B3.60 EPS next Y11.80% ROA-106.90% Target Price5.88 Perf Year-66.08%
Cash/sh0.56 P/C3.07 EPS next 5Y- ROE-125.90% 52W Range0.98 - 6.89 Perf YTD-66.60%
Dividend- P/FCF- EPS past 5Y-4.50% ROI- 52W High-74.89% Beta0.46
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low76.53% ATR0.13
Employees24 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)77.45 Volatility17.54% 8.34%
OptionableYes Debt/Eq0.00 EPS Q/Q38.10% Profit Margin- Rel Volume5.95 Prev Close1.61
ShortableYes LT Debt/Eq0.00 EarningsNov 01 BMO Payout- Avg Volume320.34K Price1.73
Recom2.30 SMA2030.96% SMA5032.31% SMA200-24.77% Volume1,905,711 Change7.45%
Aug-16-17Reiterated Needham Buy $9 → $7
Mar-21-17Reiterated Needham Buy $12 → $9
Mar-21-17Downgrade Jefferies Buy → Hold
Oct-17-17 04:30PM  Aevi Genomic Medicine Announces Completion of $28 Million Private Placement PR Newswire
Sep-14-17 06:43PM  Is Aevi Genomic Medicine Inc (GNMX) Undervalued? Simply Wall St.
Sep-05-17 08:00AM  Aevi Genomic Medicine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference PR Newswire
Aug-28-17 01:00PM  GNMX: AEVI-001 Data Mid-2018, Next Value Inflection Point? Zacks Small Cap Research
Aug-10-17 06:15AM  Aevi Genomic Medicine Announces Agreement for $28 Million Private Placement PR Newswire +13.91%
Aug-09-17 05:31PM  Aevi Genomic Medicine Reports Second Quarter 2017 Financial Results PR Newswire
Jun-13-17 08:00AM  Aevi Genomic Medicine to Present at the JMP Securities Life Sciences Conference PR Newswire +8.85%
May-11-17 08:15AM  Blog Coverage: Aevi Genomics Announces Phase 2 Clinical Trial and Reports Q1 2017 Results Accesswire
May-10-17 08:00AM  Investor Network: Aevi Genomic Medicine, Inc. to Host Earnings Call Accesswire -9.04%
08:00AM  Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 and First Quarter 2017 Operating Results Marketwired
May-03-17 08:00AM  Aevi Genomic Medicine to Host Conference Call to Announce First Quarter and Discuss Recent Business Updates Marketwired
Apr-27-17 08:00AM  Aevi Genomic Medicine to Present at the 42nd Annual Deutsche Bank Health Care Conference Marketwired +5.84%
Apr-26-17 03:00PM  GNMX: New SAGA Data May Be Just What The Doctor Ordered Zacks Small Cap Research
Apr-20-17 04:30PM  Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD Marketwired
Apr-12-17 04:30PM  Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD Marketwired +5.56%
Mar-30-17 08:00AM  Aevi Genomic Medicine to Present at the 16th Annual Needham Healthcare Conference Marketwired
Mar-28-17 11:00AM  GNMX: SAGA Misses Primary Endpoint But Data Warrants Optimism Zacks Small Cap Research
Mar-22-17 09:30AM  Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi Genomic Medicine Accesswire
Mar-21-17 06:33AM  Aevi Genomic Medicine downgraded by Jefferies -20.81%
Mar-20-17 01:28PM  Why Aevi Genomic Medicine Got Crushed Today Motley Fool -59.38%
01:28PM  Why Aevi Genomic Medicine Got Crushed Today at Motley Fool
10:23AM  AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
07:00AM  Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 Marketwired
Mar-15-17 08:00AM  Aevi Genomic Medicine to Present at the Oppenheimer 27th Annual Healthcare Conference Marketwired
Mar-14-17 01:04PM  AEVI GENOMIC MEDICINE, INC. Financials -7.25%
Mar-09-17 08:01AM  AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:30AM  Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update Marketwired
Feb-27-17 11:53AM  AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure +7.58%
08:00AM  Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference Marketwired
Feb-21-17 05:27PM  Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children's Hospital of Philadelphia Marketwired
Feb-15-17 08:00AM  Aevi Genomic Medicine Announces 2017 Investor Day Marketwired
Feb-09-17 08:00AM  Aevi Genomic Medicine to Present at the Leerink Partners 6th Annual Global Healthcare Conference Marketwired
Feb-06-17 12:28PM  [$$] Clinical Development News, Jan. 30-Feb. 3 at The Wall Street Journal
Jan-31-17 08:00AM  Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome Marketwired
Jan-04-17 08:00AM  Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents Marketwired
Dec-23-16 11:40AM  Aevi Genomic Medicine, Inc. :GNMX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 23, 2016
Dec-15-16 08:31AM  AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Othe
Aevi Genomic Medicine, Inc., a clinical stage medical technology company, engages in the research and development of products in the field of biotechnology and associated medical equipment in the United States. The company develops transduced autologous restorative gene therapy (TARGT), a platform to provide protein and peptide therapies to treat a range of chronic diseases. Its lead product candidate is MDGN-201, which is an endogenous erythropoietin secretion TARGT that is in the Phase I/II clinical trials for the treatment of end stage renal diseases and other indications, including ß-thalassemia. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duncan Barbara GayleDirectorOct 17Buy1.2659,52475,00059,524Oct 18 04:16 PM
CLEMOW ALASTAIR JDirectorOct 17Buy1.2619,84125,00057,536Oct 18 04:17 PM
BAUER EUGENE ADirectorOct 17Buy1.2619,84125,000165,715Oct 18 04:17 PM
COLA MICHAEL FPresident and CEOOct 17Buy1.26119,047149,999218,483Oct 18 04:17 PM
NEIL GARRY ARTHURChief Scientific OfficerOct 17Buy1.2675,00094,500114,774Oct 18 04:16 PM
GANTZ WILBUR HDirectorOct 17Buy1.2639,68350,00171,073Oct 18 04:16 PM
BARER SOL JDirectorOct 17Buy1.26421,032530,5001,028,032Oct 18 04:15 PM
HARPER PHILIP R10% OwnerSep 01Buy1.2083,775100,5304,959,819Sep 06 11:21 AM